Sun Pharmaceutical Industries introduces its global innovative medication, Ilumya (Tildrakizumab), in India for moderate to severe plaque psoriasis. Ilumya, a new biologic therapy, has been broadly supported by dermatologists in the US
.png "Lupin Secures FDA Approval for Armlupeg Biosimilar Drug")
Lupin has obtained U.S. FDA approval of Armlupeg, a biosimilar of Neulasta. The product is pegfilgrastim 6mg/0.6ml prefilled injection in a single-dose syringe to be used as a subcutaneous injection. The manufacturing will be done in the biotech...
Cloud software leader Veeva Vault CRM is getting a major boost today as Veeva Systems deepens its long-standing partnership with Swiss healthcare powerhouse Roche Pharmaceuticals. The new agreement brings a full global deployment of Veeva’s...
RPG Life Sciences is stepping into India’s growing GLP-1 market — targeting obesity and diabetes — and laying the groundwork for a bold expansion that could reshape its future. The company has outlined an ambition to reach ?2,500 crore turnover...
The Union health ministry's Drugs Consultative Committee (DCC) has advised the government to modify the Drugs and Cosmetic Rules (D&C Rules) to grant licenses to pharmaceutical marketers under specific conditions aimed at guaranteeing the quality
Himalaya Wellness has teamed up with Unicommerce, one of India’s top e-commerce enablement SaaS platforms, to streamline its online operations and accelerate its omnichannel expansion
Cipla Limited has unveiled its first Breathefree Lung Wellness Centre in Lajpat Nagar, New Delhi—marking the debut of India’s first integrated lung diagnostics and wellness facility
Lupin Human Welfare and Research Foundation (LHWRF), the CSR wing of global pharmaceutical leader Lupin Limited, has earned the top-tier CRISIL Voluntary Organisation rating of VO 1A—a distinction that signifies exceptional program delivery
.png "Biocon Biologics Wins USFDA VAI Classification for Bengaluru Unit")
Biocon Biologics received an important update from the US FDA. The agency now has listed the Drug Substance Facility of the company in Bengaluru as Voluntary Action Indicated (VAI). This declaration is one of the major achievements of the...
Zydus Lifesciences has obtained a provisional license from the U.S. Food and Drug Administration on Empagliflozin and Linagliptin pills. This is a milestone in the U.S. expanding portfolio of the company. It reports about the generic Glyxambi...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")